EVALUATING THE COST-EFFECTIVENESS OF BARIATRIC SURGERY, INCRETIN-BASED THERAPY, AND LIFESTYLE MODIFICATION FOR OBESITY IN OMAN
Author(s)
kareem Elfass, BSc, MSc1, Said Wani, BSc, MSc2, Asiya AL Kindi, BSc, MSc3, Manal Alansari, BSc, MSc4, Ibrahim AlRashdi, BSc, MSc2, Sara Al Balushi, PhD2, Raid Alsabiri, B.Pharm, MScc, MBA2, Safiya Al Muaini, BSc, MSc4, Anisa Rasool, BSc2, Khulood Almutawa, MSc2, Isra Al lawati, MSc2, Alia Al Suhaily, MSc5, Sherif Abaza, MBA6, Balázs Nagy, PhD7, Ahmad Fasseeh, PhD1, Zoltan Kalo, PhD8.
1Syreon Middle East, Alexandria, Egypt, 2Ministry of Health - Oman, Muscat, Oman, 3Minsitry Of Health- Oman, Muscat, Oman, 4Ministry of Health - Oman, MUSCAT, Oman, 5Ministry of Health- Oman, Muscat, Oman, 6Syreon Middle East, Cairo, Egypt, 7Syreon Research Institute, Budapest, Hungary, 8Center for Health Technology Assessment, Semmelweis University & Syreon Research Institute, Budapest, Hungary.
1Syreon Middle East, Alexandria, Egypt, 2Ministry of Health - Oman, Muscat, Oman, 3Minsitry Of Health- Oman, Muscat, Oman, 4Ministry of Health - Oman, MUSCAT, Oman, 5Ministry of Health- Oman, Muscat, Oman, 6Syreon Middle East, Cairo, Egypt, 7Syreon Research Institute, Budapest, Hungary, 8Center for Health Technology Assessment, Semmelweis University & Syreon Research Institute, Budapest, Hungary.
OBJECTIVES: Obesity is a growing clinical and economic burden in Oman, contributing to cardiometabolic diseases and putting more pressure on limited healthcare resources. Comparative evidence on the cost-effectiveness of bariatric surgery, pharmacotherapy, and lifestyle changes is essential to guide policy decisions.
METHODS: A whole-disease, patient-level simulation model of obesity was developed from the perspective of the Oman Ministry of Health. A synthetic cohort of adults with obesity was simulated over a lifetime horizon using 6-month cycles and a 3% discount rate. Interventions included laparoscopic sleeve gastrectomy (LSG), laparoscopic Roux-en-Y gastric bypass (LRYGB), one-anastomosis gastric bypass (OAGB), semaglutide 2.4mg weekly, tirzepatide 5mg weekly, lifestyle intervention, and no treatment. Outcomes assessed included costs, quality-adjusted life-years (QALYs), and the payback period.
RESULTS: No intervention had the highest costs (OMR 77,467) and lowest outcomes (15.43 QALYs). All interventions were dominant, improving outcomes while reducing costs. LRYGB showed the greatest benefit (+2.76 QALYs; −OMR 20,395), followed by OAGB and LSG. Tirzepatide and semaglutide also provided gains, with smaller improvements for lifestyle intervention. Break-even for healthcare costs occurred earliest with surgery (4-6 years), followed by pharmacotherapy (13-15 years) and lifestyle intervention (18-19 years).
CONCLUSIONS: All interventions improved outcomes and reduced long-term costs. Bariatric surgery offers the highest value and the fastest return on investment, supporting its priority along with targeted use of other therapies.
METHODS: A whole-disease, patient-level simulation model of obesity was developed from the perspective of the Oman Ministry of Health. A synthetic cohort of adults with obesity was simulated over a lifetime horizon using 6-month cycles and a 3% discount rate. Interventions included laparoscopic sleeve gastrectomy (LSG), laparoscopic Roux-en-Y gastric bypass (LRYGB), one-anastomosis gastric bypass (OAGB), semaglutide 2.4mg weekly, tirzepatide 5mg weekly, lifestyle intervention, and no treatment. Outcomes assessed included costs, quality-adjusted life-years (QALYs), and the payback period.
RESULTS: No intervention had the highest costs (OMR 77,467) and lowest outcomes (15.43 QALYs). All interventions were dominant, improving outcomes while reducing costs. LRYGB showed the greatest benefit (+2.76 QALYs; −OMR 20,395), followed by OAGB and LSG. Tirzepatide and semaglutide also provided gains, with smaller improvements for lifestyle intervention. Break-even for healthcare costs occurred earliest with surgery (4-6 years), followed by pharmacotherapy (13-15 years) and lifestyle intervention (18-19 years).
CONCLUSIONS: All interventions improved outcomes and reduced long-term costs. Bariatric surgery offers the highest value and the fastest return on investment, supporting its priority along with targeted use of other therapies.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE24
Topic
Economic Evaluation, Health Policy & Regulatory, Health Technology Assessment
Topic Subcategory
Thresholds & Opportunity Cost
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity), No Additional Disease & Conditions/Specialized Treatment Areas